riluzole has been researched along with Tourette Syndrome in 2 studies
Riluzole: A glutamate antagonist (RECEPTORS, GLUTAMATE) used as an anticonvulsant (ANTICONVULSANTS) and to prolong the survival of patients with AMYOTROPHIC LATERAL SCLEROSIS.
Tourette Syndrome: A neuropsychological disorder related to alterations in DOPAMINE metabolism and neurotransmission involving frontal-subcortical neuronal circuits. Both multiple motor and one or more vocal tics need to be present with TICS occurring many times a day, nearly daily, over a period of more than one year. The onset is before age 18 and the disturbance is not due to direct physiological effects of a substance or another medical condition. The disturbance causes marked distress or significant impairment in social, occupational, or other important areas of functioning. (From DSM-IV, 1994; Neurol Clin 1997 May;15(2):357-79)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Lemmon, ME | 1 |
Grados, M | 2 |
Kline, T | 1 |
Thompson, CB | 1 |
Ali, SF | 1 |
Singer, HS | 2 |
Morris, C | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Combined PET and MR Investigations of the Pathophysiology of Gilles de la Tourette Syndrome. Part 1: Simultaneous PET and 3T MRI[NCT05232955] | 40 participants (Anticipated) | Observational | 2022-02-28 | Not yet recruiting | |||
Combined PET and MR Investigations of the Pathophysiology of Gilles de la Tourette Syndrome. Part 2: 7T MRI[NCT05233306] | 60 participants (Anticipated) | Observational | 2022-01-27 | Recruiting | |||
Double-Blind, Placebo-Controlled Trial of N-acetylcysteine (NAC) for the Treatment of Children With Tourette Syndrome[NCT01172288] | Phase 2 | 31 participants (Actual) | Interventional | 2010-07-31 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Childrens' Yale-Brown Obsessive-Compulsive Scale (CY-BOCS). 10-item scale. Each item is rated from 0-4. A sum total is calculated by adding items 1-10. 0-7: Subclinical. 8-15: Mild. 16-23: Moderate. 24-31: Severe. 32-40: Extreme. (NCT01172288)
Timeframe: 12 weeks
Intervention | units on a scale (Mean) |
---|---|
N-Acetylcysteine | 4.4 |
Placebo | 11.5 |
"Yale Global Tic Severity Scale is a standard psychiatric measure that rates tics from 0 (no tics) to 100 (most severe tics).~It separately rates motor tics and vocal tics in 5 subscales (number, frequency, intensity, complexity and interference) where the maximum severity score for motor tics is 25 and for vocal tics is 25. Giving us the Total Tic Severity Score maximum of 50.~The additional Impairment Scale rates the degree of disability caused by the tics ranging from 0 (none) to 50 (severe). When these two scores are added we get the Yale Global Tic Severity Scale Score." (NCT01172288)
Timeframe: 12 weeks
Intervention | units on a scale (Mean) |
---|---|
N-Acetylcysteine | 24.3 |
Placebo | 21.3 |
"Premonitory Urge for Tics Scale (PUTS). Items are rated on a scale of 1-4 from least to most. A total score is calculated by summing the scores of all items. Nine is the minimum possible score. A score of 12.5-24.5 indicates medium intensity of premonitory urges for tics. A score of 25-30.5 indicates high intensity which may be associated with marked impairment. Scores 31 and above indicate extremely high intensity with probable severe impairment. A score of 36 is the maximum score possible." (NCT01172288)
Timeframe: 12 weeks
Intervention | units on a scale (Mean) |
---|---|
N-Acetylcysteine | 24.7 |
Placebo | 24.1 |
Clinical Global Impression - Improvement Scale (CGI-I). The CGI is a 7-point scare that requires the clinician to assess how much the patient's illness has improved or worsened relative to a baseline state at the beginning of the intervention. 1 = Very much improved; 2 = Much improved; 3 = Minimally improved; 4 = No change; 5 = Minimally worse; 6 = Much worse; 7 = Very much worse. (NCT01172288)
Timeframe: 12 weeks
Intervention | units on a scale (Mean) |
---|---|
N-Acetylcysteine | 3.3 |
Placebo | 3.4 |
Number of participants with adverse events according to the Pediatric Adverse Events Rating Scale (NCT01172288)
Timeframe: 12 weeks
Intervention | participants (Number) | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Irritability | Sadness or depressed mood | Fatigue | Insomnia | Decreased appetite | Chest pain | Syncope | Stomach ache | Nausea | Vomiting | Headache | |
N-Acetylcysteine | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
Placebo | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 2 | 3 | 0 | 1 |
1 trial available for riluzole and Tourette Syndrome
Article | Year |
---|---|
Efficacy of Glutamate Modulators in Tic Suppression: A Double-Blind, Randomized Control Trial of D-serine and Riluzole in Tourette Syndrome.
Topics: Adolescent; Child; Double-Blind Method; Excitatory Amino Acid Antagonists; Female; Humans; Male; Ril | 2015 |
1 other study available for riluzole and Tourette Syndrome
Article | Year |
---|---|
Glutamatergic modulatory therapy for Tourette syndrome.
Topics: Cycloserine; Dopamine; Excitatory Amino Acid Agonists; Excitatory Amino Acid Antagonists; Glutamic A | 2010 |
Glutamatergic modulatory therapy for Tourette syndrome.
Topics: Cycloserine; Dopamine; Excitatory Amino Acid Agonists; Excitatory Amino Acid Antagonists; Glutamic A | 2010 |
Glutamatergic modulatory therapy for Tourette syndrome.
Topics: Cycloserine; Dopamine; Excitatory Amino Acid Agonists; Excitatory Amino Acid Antagonists; Glutamic A | 2010 |
Glutamatergic modulatory therapy for Tourette syndrome.
Topics: Cycloserine; Dopamine; Excitatory Amino Acid Agonists; Excitatory Amino Acid Antagonists; Glutamic A | 2010 |
Glutamatergic modulatory therapy for Tourette syndrome.
Topics: Cycloserine; Dopamine; Excitatory Amino Acid Agonists; Excitatory Amino Acid Antagonists; Glutamic A | 2010 |
Glutamatergic modulatory therapy for Tourette syndrome.
Topics: Cycloserine; Dopamine; Excitatory Amino Acid Agonists; Excitatory Amino Acid Antagonists; Glutamic A | 2010 |
Glutamatergic modulatory therapy for Tourette syndrome.
Topics: Cycloserine; Dopamine; Excitatory Amino Acid Agonists; Excitatory Amino Acid Antagonists; Glutamic A | 2010 |
Glutamatergic modulatory therapy for Tourette syndrome.
Topics: Cycloserine; Dopamine; Excitatory Amino Acid Agonists; Excitatory Amino Acid Antagonists; Glutamic A | 2010 |
Glutamatergic modulatory therapy for Tourette syndrome.
Topics: Cycloserine; Dopamine; Excitatory Amino Acid Agonists; Excitatory Amino Acid Antagonists; Glutamic A | 2010 |